| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/16/2010 | US7662824 (S)-4-Bromo-3-[(2-2,3-dihydro-benzofuran-5-yl-acetyl)-hydrazono]-2-oxo-2,3-dihydro-1H-indole-6-carboxylic acid [3-(2-hydroxymethyl-pyrrolidin-1-yl)-propyl]-amide; for treating conditions such as cancers and other cell proliferative disorders |
| 02/16/2010 | US7662823 non-nucleoside reverse transcriptase inhibitors; for treatment of HIV and AIDS |
| 02/16/2010 | US7662822 Substituted azaquinazolines having an antiviral action |
| 02/16/2010 | US7662821 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
| 02/16/2010 | US7662820 Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon |
| 02/16/2010 | US7662819 Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors |
| 02/16/2010 | US7662818 e.g. 4-[5-(piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; and multiple sclerosis |
| 02/16/2010 | US7662817 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever; irritable bowel syndrome |
| 02/16/2010 | US7662816 Cognition activators; neurodegenerative disorders; Alzheimer's disease |
| 02/16/2010 | US7662815 Treating pulmonary diseases, asthma, chronic obstructive pulmonary disease, chronic bronchitis, pre-term labor, neurological and cardiac disorders; improved duration of action, potency, selectivity; 8-hydroxy-5-((R)-1-hydroxy-2-{2-[4-(6-methoxybiphenyl-3-yloxy)phenyl]-ethylamino}ethyl)-1H-quinolin-2-one |
| 02/16/2010 | US7662814 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases |
| 02/16/2010 | US7662813 Triazole compounds that modulate HSP90 activity |
| 02/16/2010 | US7662812 disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances |
| 02/16/2010 | US7662811 1,2,3,4-tetrahydropyrazin-2-yl acetamides and methods of use |
| 02/16/2010 | US7662810 2-arylmethylazetidine carbapenem derivatives and preparation thereof |
| 02/16/2010 | US7662809 13-Cyclohexyl-5-(2-pyrrolidin-1-ylethoxy)-6,7-dihydro-5H-indolo[2.1-a][2]benzazepine-10-carboxylic acid, for example; use for the treatment or prevention of infection by hepatitis C virus |
| 02/16/2010 | US7662808 Diazabicyclic aryl derivatives as cholinergic receptor modulators |
| 02/16/2010 | US7662807 Sulphonated meso-tetraphenyl chlorins |
| 02/16/2010 | US7662805 Mixture of antidepressant such as serotonine receptor antagonist, with acetylsalicylic acid |
| 02/16/2010 | US7662804 Selective, tissue-specific TPO receptor agonists; thrombocytopenia resulting from radiation or chemotherapy; drug screening; [(N-substituted-2-oxo-1,2-dihydroindol-3-ylidene)hydrazino]-2-phenols; amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injuries, muscular dystrophy |
| 02/16/2010 | US7662801 Biodegradable oxidized cellulose esters |
| 02/16/2010 | US7662800 Hyaluronic acid derivatives |
| 02/16/2010 | US7662799 Powder of amino acids and method for producing the same |
| 02/16/2010 | US7662798 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| 02/16/2010 | US7662796 Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1 |
| 02/16/2010 | US7662795 Enhancement of adenoviral oncolytic activity by modification of the E1A gene product |
| 02/16/2010 | US7662794 DNA enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/16/2010 | US7662793 Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter |
| 02/16/2010 | US7662792 Modulation of Fas and FasL expression |
| 02/16/2010 | US7662790 Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| 02/16/2010 | US7662788 Abuse-resistant amphetamine prodrugs |
| 02/16/2010 | US7662787 lisdexamfetamine, lisdexamfetamine dimesylate and lisdexamfetamine hydrochloride; attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity |
| 02/16/2010 | US7662771 Drug delivery; controlled/sustained release |
| 02/16/2010 | US7662767 inhibiting complexation of intercalating molecules with polynucleotides; using modified xanthine molecules as a binding agent; drug delivery system for compounds that have low solubility in aqueous media, including anti-neoplastic agents |
| 02/16/2010 | US7662750 Protein-protein interaction antagonist screening libraries based upon 1,4-disubstituted naphthalenes and related scaffolds |
| 02/16/2010 | US7662748 Formulations comprising triazoles and alkoxylated amines |
| 02/16/2010 | US7662627 Adeno-associated virus materials and methods |
| 02/16/2010 | US7662619 Addition of histidine amino acids to the cytoplasmic domains of membrane and viral envelope proteins for the purpose of solubilizing, and/or reconstituting viral envelope proteins in lipid containing vesicles |
| 02/16/2010 | US7662553 Polymorphisms in the ERCC1 gene for predicting treatment outcome |
| 02/16/2010 | US7662418 Preparation of high viscosity beta-glucan concentrates |
| 02/16/2010 | US7662407 Modified release formulations of a bupropion salt |
| 02/16/2010 | US7662394 Nucleic acids encoding chimeric Flavivirus immunogens comprising the Japanese encephalitis virus (JEV) PRM signal sequence |
| 02/16/2010 | US7662389 Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
| 02/16/2010 | US7662374 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 02/16/2010 | US7662373 Comprising an emulsifier, a bowel relaxant and one or more chelating agents to absorb and mechanically agitate non-digested fats; decreased side effects |
| 02/16/2010 | US7662365 Polymer conjugates of opioid antagonists |
| 02/16/2010 | US7662364 Drug for hyperphospheremia and its preparative method |
| 02/16/2010 | CA2628224C Vinyl-pyrrolidinone cephalosporins with basic substituents |
| 02/16/2010 | CA2575003C Potassium channel inhibitors |
| 02/16/2010 | CA2571627C Substituted aryl-amine derivatives and methods of use |
| 02/16/2010 | CA2562532C Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same |
| 02/16/2010 | CA2556175C Calcium formate for use as a phosphorus binder and a dietary supplement |
| 02/16/2010 | CA2539985C Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
| 02/16/2010 | CA2537414C .beta. crystalline form of ivabradine chlorhydrate, process for the preparation thereof and pharmaceutical compounds containing it |
| 02/16/2010 | CA2528008C 2-substituted phenyl-5,7-dialkyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof |
| 02/16/2010 | CA2479274C Thiazolidinedione derivatives and pharmaceutical composition comprising the same |
| 02/16/2010 | CA2478183C Substituted amides |
| 02/16/2010 | CA2462482C Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
| 02/16/2010 | CA2455740C Insect repellent comprising hydrated unsaturated monoterpenoid and c6-c13 carboxylic acid |
| 02/16/2010 | CA2455224C Use of pyrimidine nucleosides and/or the prodrugs thereof for combating the side-effects of haart (highly active anti-retroviral therapy) and other anti-viral therapies |
| 02/16/2010 | CA2452918C New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 02/16/2010 | CA2450922C Piperidines for use as orexin receptor antagonists |
| 02/16/2010 | CA2447175C Use of estrogen compounds to increase libido in women |
| 02/16/2010 | CA2445329C 20-hydroxyeicosatetraenoic acid production inhibitors |
| 02/16/2010 | CA2442882C Sulphones which modulate the action of gamma-secretase |
| 02/16/2010 | CA2440037C Benzimidazole derivatives for modulating the rage receptor |
| 02/16/2010 | CA2438961C Beta-lactam compounds, manufacturing methods of the compounds and serum hypocholesterolemic agents containing the compounds |
| 02/16/2010 | CA2430001C Light stabilized antimicrobial materials |
| 02/16/2010 | CA2429109C Anti-inflammatory agents |
| 02/16/2010 | CA2426682C Intraoral rapid-disintegrating medicinal compositions and production process thereof |
| 02/16/2010 | CA2422267C Drying method for selectively removing volatile components from wet coatings |
| 02/16/2010 | CA2410939C Materials and methods for the treatment of gastroesophageal reflux disease |
| 02/16/2010 | CA2410399C 5-aminoalkylpyrazolo[4,3-d]pyrimidines |
| 02/16/2010 | CA2407043C Naphthamidine urokinase inhibitors |
| 02/16/2010 | CA2406095C Synthetic process for the manufacture of an ecteinaschidin compound |
| 02/16/2010 | CA2405531C Microencapsulated fragrances and methods of coating microcapsules |
| 02/16/2010 | CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 02/16/2010 | CA2385938C Cyclic amine compounds as ccr5 antagonists |
| 02/16/2010 | CA2371912C Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| 02/16/2010 | CA2368626C Cilostazol preparation |
| 02/16/2010 | CA2346082C Tricyclic .delta.3-piperidines as pharmaceuticals |
| 02/16/2010 | CA2344435C Compositions for the treatment of male erectile dysfunction |
| 02/16/2010 | CA2341707C Pyrimidine derivatives |
| 02/16/2010 | CA2313858C Microporous films comprising flocked fibers |
| 02/16/2010 | CA2309154C Substituted porphyrins |
| 02/16/2010 | CA2308551C Phenanthroline derivatives |
| 02/16/2010 | CA2287387C Methods and compositions for destruction of selected proteins |
| 02/16/2010 | CA2274510C Treatment of osteoarthritis by administering poly-n-acetyl-d-glucosamine |
| 02/16/2010 | CA2266748C Three component chimeric antisense oligonucleotides |
| 02/16/2010 | CA2225822C Nitroimidazole antibacterial compounds and methods of use thereof |
| 02/16/2010 | CA2220433C Il-6 activity inhibitor |
| 02/16/2010 | CA2204254C Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand |
| 02/13/2010 | CA2638175A1 Methods for treating or preventing neuroinflammation or autoimmune disease |
| 02/11/2010 | WO2010017550A2 Lipid compounds for supression of tumorigenesis |
| 02/11/2010 | WO2010017545A2 Triazole compounds that modulate hsp90 activity |
| 02/11/2010 | WO2010017541A2 Compositions and methods for treatment of neurodegenerative disease |
| 02/11/2010 | WO2010017509A1 Modulation of transthyretin expression for the treatment of cns related disorders |
| 02/11/2010 | WO2010017480A1 Glycoside compounds and pharmaceutical compositions thereof |
| 02/11/2010 | WO2010017479A1 Triazole compounds that modulate hsp90 activity |
| 02/11/2010 | WO2010017478A2 Pak1 agonists and methods of use |